149488-39-1 Usage
Chemical class
Thiourea derivative
Structural features
Substituted phenyl ring
Pyridine ring
Potential applications
Medicinal chemistry
Biological activity
Possible, due to structural features
Ongoing research
Synthesis, properties, and potential uses
Functional groups
Ethoxy group (-OCH2CH3)
Fluoro group (-F)
Methyl group (-CH3)
Thiourea group (-NH-C(=S)-NH-)
Structural complexity
Moderate, due to multiple functional groups and heteroatoms
Solubility
Unknown, but may vary depending on solvent polarity
Stability
Unknown, but may be influenced by the presence of the thiourea group and other functional groups
Reactivity
Potentially reactive due to the presence of the thiourea group and other functional groups
Synthesis
May involve multi-step reactions, including the formation of the phenyl and pyridine rings, and subsequent functionalization
Analytical techniques
NMR, IR, and mass spectrometry for structural elucidation
Purity
May be assessed using techniques like high-performance liquid chromatography (HPLC) or gas chromatography (GC)
Safety
Unknown, but should be handled with care due to potential reactivity and unknown biological activity
Check Digit Verification of cas no
The CAS Registry Mumber 149488-39-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,9,4,8 and 8 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 149488-39:
(8*1)+(7*4)+(6*9)+(5*4)+(4*8)+(3*8)+(2*3)+(1*9)=181
181 % 10 = 1
So 149488-39-1 is a valid CAS Registry Number.
149488-39-1Relevant articles and documents
Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs
Bell,Cantrell,Hogberg,Jaskunas,Johansson,Jordan,Kinnick,Lind,Morin Jr.,Noreen,Oberg,Palkowitz,Parrish,Pranc,Sahlberg,Ternansky,Vasileff,Vrang,West,et al.
, p. 4929 - 4936 (2007/10/03)
A novel series of potent specific HIV-1 inhibitory compounds is described. The lead compound in the series, N-(2-phenethyl)-N'-(2-thiazolyl)thiourea (1), inhibits HIV-1 RT using rCdG as the template with an IC50 of 0.9 μM. In MT-4 cells, compound 1 inhibits HIV-1 with an ED50 of 1.3 μM. The 50% cytotoxic dose in cell culture is >380 μM. The chemical structure-activity relationship (SAR) was developed by notionally dividing the lead compound in four quadrants. The SAR strategy had two phases. The first phase involved optimization of antiviral activity through independent variation of quadrants 1-4. The second phase involved the preparation of hybrid structures combining the best of these substituents. Further SAR studies and pharmacokinetic considerations led to the identification of N-(2-pyridyl)-N'-(5-bromo-2- pyridyl)-thiourea (62; LY300046 · HCl) as a candidate for clinical evaluation. LY300046 · HCl inhibits HIV-1 RT with an IC50 of 15 nM and in cell culture has an ED50 of 20 nM.
